Hacker News Reader

Not sure I agree, the drug manufacturing is not equal drug manufacturing. Production of a small molecule therapeutic (e.g. Remdesivir) requires very different capabilities of biotherapeutic manufacturing (e.g. antibodies). mRNA manufacturing is a different beast alltogether.

View on HN

AFAIK, the main issue is transport, not manufacturing capability. The reason the latter is so tightly controlled is because it's not difficult once the process is known. And African countries are experienced in the former.

Reply on news.ycombinator.com